Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDH-111
- Development stage
- Unknown
- Lead developer
- MD Healthcare
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Inhalation
01
Overview
MDH-111 is an inhaled microbial extracellular vesicle (EV)-based therapeutic derived from the commensal bacterium *Micrococcus luteus*. Developed by MD Healthcare, MDH-111 is designed to treat chronic inflammatory respiratory diseases, including non-eosinophilic (neutrophilic) asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis, anosmia, and chronic rhinosinusitis. The therapeutic works by upregulating hsa-miR-4517 expression in airway epithelial cells, which subsequently suppresses IL-1β production by monocytes, inhibits group 3 innate lymphoid cell (ILC3) activation, and reduces neutrophil recruitment. By suppressing Th17-mediated neutrophilic inflammation and preventing epithelial cell apoptosis, MDH-111 aims to modify the underlying disease course of steroid-resistant respiratory conditions. It is currently in Phase 1 clinical development.
- Other names
- Micrococcus luteus-derived extracellular vesicleMicrococcus luteus-derived extracellular vesiclesMlEVMlEVs
Beyond the preview
Go deeper on MDH-111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDH-111.